Jeff Cislini - 18 Nov 2025 Form 4 Insider Report for Revolution Medicines, Inc. (RVMD)

Signature
/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini
Issuer symbol
RVMD
Transactions as of
18 Nov 2025
Transactions value $
-$370,687
Form type
4
Filing time
20 Nov 2025, 16:23:35
Previous filing
20 Oct 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Cislini Jeff General Counsel C/O REVOLUTION MEDICINES, INC., 700 SAGINAW DRIVE, REDWOOD CITY /s/ Jack Anders, as Attorney-in-fact for Jeff Cislini 20 Nov 2025 0001969082

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVMD Common Stock Options Exercise $568K +13.4K +26.55% $42.45 63.8K 18 Nov 2025 Direct F1, F2
transaction RVMD Common Stock Sale -$939K -13.4K -20.98% $70.14 50.4K 18 Nov 2025 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RVMD Stock Option (Right to Buy) Options Exercise $0 -13.4K -100% $0.00 0 18 Nov 2025 Common Stock 13.4K $42.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 13, 2025.
F2 Includes 43,910 restricted stock units.
F3 This transaction was executed in multiple trades in prices ranging from $70.00 to $70.38, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.